For patients with PD-L1–negative lung cancer, combination chemoimmunotherapy with a platinum-based doublet is an emerging standard of care.22 In either setting, platinum-based doublet chemotherapy will continue to play an important role for most patients with metastatic lung cancer, highlighting the ongoing relevance of the findings reported here. The gene discussed is CD274; the disease is lung carcinoma.